Member Info for LordSnooty

.

.

regarding iWeb - as stated, a trade is only £5, but I've had an account for more than ten years and when I opened it, it was free. I just looked at their website and it appears opening a new account now costs £200. Check it out, but if that's the case, an IG account may be better - though to trade XBIO will cost $15 a pop. Best check out your options yourself.

http://www.insidermonkey.com/blog/for-shire-plc-adr-shpg-securing-hemophilia-market-with-long-acting-version-is-crucial-514953/?utm_source=Stocktwits&utm_campaign=dnan&utm_medium=Social

Yorkie - one had hopes some months ago that Leeson had been shot into space and was headed for Alpha Centauri at close to light speed. However, just as one was beginning to enjoy a tranquil uplift to NASDAQ down here on Earth, it appeared a hologram of his entire catalogue of bad jokes was left behind as a parting 'gift'.

Yes Clem, iWeb at £5 a pop. IG will also trade the shares at $15 a trade

Move...

Interesting RNS from Shire today: Directorate change Appointment of Ian Clark as Non-Executive Director January 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (Shire/ the Company) announces the appointment of Ian Clark as a Non-Executive Director of the Company with effect from the date of this announcement. Mr. Clark served as Chief Executive Officer and Director of Genentech Inc (part of the Roche Group) and Head of North American Commercial Operations for Roche until December 31, 2016, having held several senior strategy, operations and commercially focused roles since joining Genentech in 2003. Prior to this Mr. Clark held various senior operational, sales and marketing roles in other pharmaceutical and healthcare companies. He is currently appointed as a Non-Executive Director of TerraVia Holdings Inc. where he serves as Chairman of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. Susan Kilsby, Shires Chairman, commented: We are very pleased to announce Ians appointment at this important time; his in-depth knowledge of the biotechnology sector and breadth of operational experience stand to serve Shire well as we look forward to growing our business and addressing unmet patient needs world-wide. Mr. Clark added: Shire has demonstrated commitment to being the global leader in rare diseases and to delivering value to its patients, physicians, shareholders and other stakeholders. I look forward to working with Susan and the rest of the Board in pursuing a successful future for the Company. Note that Mr Clark has jumped ship from a Roche subsidiary to Shire, a major investor in XBIO.

Ace - if you've been in LPO, XEN or XBIO for any length of time, I'm sure you know how opaque pharmas can be about their plans and machinations, and how things almost never happen when they say they will. Last Friday's move was, I hope, the beginning of a rise to a more reasonable valuation. Scott did imply a year or two ago that PIs would not be able to participate in the IPO but would get their chance of some cheap shares - well, we sat at $3.50 or thereabouts for a month or two after the IPO, many of us, myself included, very ****ed off that our AIM investments were now worth half or less than what we bought them for five or more years ago. I took the opportunity to add a few shares, but not as many as I'd have felt comfortable with previously. Even now, we are still at little more than a quarter of what OPKO paid for a slice a year ago, so to me it's still a bargain, even given the dilution - if you have any confidence left after the last few years. For me, I still think there's nothing wrong with the science, so the share will come good, it just takes the patience of Job.

Ace - you've got me there, but wasn't it Phase IIa data that was originally planned to be released in December?

Ace - I gather that, shortly after the CC, Scott received word from Shire they had changed their plans and now intended not to report on Factor VIII in the short term, but rather to continue with a full Phase II, results scheduled in Q2. That's all I know. The impression I have is that such a decision is indicative that Shire are getting good data and wish to press on quickly, particularly in light of Roche's rival product encountering setbacks.

That high was probably just an aberration, but the 4k traded after the bell at 4.701 may point to further gains soon. Question is, is it just the recent in-house broker note driving the rise, or is there hard news a-coming?

a chucklemeister, a jester, a farceur, a quipster to match Leeson - at last!

Never say die! All we need is one of our many candidates to come good and we'll fly. Here's to a better 2017.

when Leeson wheels out his clunkiest jokes.

5teve - that's my sense of it.

Three days of plus 10k trades, that's a new one but it's still far short of regular good volume. For that we need not just cheap shares being fed into the market but some genuine exchange of shares between holders, which in turn demands more movement, with news as the catalyst. I hear Shire now plans not to announce PI/IIa soon but rather to proceed quickly on to a full PII of SHP656, results in Q2 next year. That, and Roche's candidate's recent setback, suggests they want to try to get this to market ASAP - good for us in the medium term.

Gave you a tick for that, 5teve.

Well it's there for the taking now, but I'm going to decline the offer; I have enough morasses already in what passes for my portfolio.

MMs wouldn't have it.